Literature DB >> 18609327

Understanding the neuropsychological profile of HIV+ participants with low literacy: role of the General Ability Measure for Adults (GAMA).

Elizabeth L Ryan1, Desiree Byrd, Monica Rivera Mindt, William J Rausch, Susan Morgello.   

Abstract

The WRAT-3 Reading subtest (WRS) may be inappropriate in diseases having disproportionate impact on populations with educational disadvantages (i.e., HIV/AIDS). To understand how low literate individuals would perform on an IQ test requiring minimal education, the General Ability Measure for Adults (GAMA) was studied. HIV+ participants completed WRS, GAMA, and neuropsychological tests. Participants with low WRS (<80 SS) but higher GAMA (>or=80 SS) had significantly better overall neuropsychological functioning than those with <80 SS on both tests. The GAMA may be a useful test when disparities in educational quality render reading-based measures of IQ a poor surrogate of premorbid function.

Entities:  

Mesh:

Year:  2008        PMID: 18609327      PMCID: PMC2696226          DOI: 10.1080/13854040701750883

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  29 in total

1.  Reading level attenuates differences in neuropsychological test performance between African American and White elders.

Authors:  Jennifer J Manly; Diane M Jacobs; Pegah Touradji; Scott A Small; Yaakov Stern
Journal:  J Int Neuropsychol Soc       Date:  2002-03       Impact factor: 2.892

2.  Reading on the Wide Range Achievement Test-Revised and parental education as predictors of IQ: comparison with the Barona formula.

Authors:  D A Kareken; R C Gur; A J Saykin
Journal:  Arch Clin Neuropsychol       Date:  1995-03       Impact factor: 2.813

Review 3.  Advantages and disadvantages of separate norms for African Americans.

Authors:  Jennifer J Manly
Journal:  Clin Neuropsychol       Date:  2005-06       Impact factor: 3.535

4.  Discrepancies between self-reported years of education and estimated reading level among elderly community-dwelling African-Americans: Analysis of the MOAANS data.

Authors:  Sid E O'Bryant; John A Lucas; Floyd B Willis; Glenn E Smith; Neill R Graff-Radford; Robert J Ivnik
Journal:  Arch Clin Neuropsychol       Date:  2007-03-02       Impact factor: 2.813

5.  Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers.

Authors:  D S Hasin; K D Trautman; G M Miele; S Samet; M Smith; J Endicott
Journal:  Am J Psychiatry       Date:  1996-09       Impact factor: 18.112

6.  Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors.

Authors:  Diana De Ronchi; Irma Faranca; Domenico Berardi; Paolo Scudellari; Marco Borderi; Roberto Manfredi; Laura Fratiglioni
Journal:  Arch Neurol       Date:  2002-05

7.  Neurocognitive correlates of socioeconomic status in kindergarten children.

Authors:  Kimberly G Noble; M Frank Norman; Martha J Farah
Journal:  Dev Sci       Date:  2005-01

8.  The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples.

Authors:  Michael C Diehr; Mariana Cherner; Tanya J Wolfson; S Walden Miller; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2003-06       Impact factor: 2.475

9.  HIV Dementia Scale: a rapid screening test.

Authors:  C Power; O A Selnes; J A Grim; J C McArthur
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-03-01

10.  Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection.

Authors:  R A Stern; S G Silva; N Chaisson; D L Evans
Journal:  Arch Neurol       Date:  1996-02
View more
  1 in total

1.  Reading Ability as an Estimator of Premorbid Intelligence: Does It Remain Stable Among Ethnically Diverse HIV+ Adults?

Authors:  James P Olsen; Robert P Fellows; Monica Rivera-Mindt; Susan Morgello; Desiree A Byrd
Journal:  Clin Neuropsychol       Date:  2015-12-21       Impact factor: 3.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.